Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125671691 | 12567169 | 1 | I | 20160713 | 20160718 | 20160718 | EXP | GB-MYLANLABS-2016M1029525 | MYLAN | WLODEK C, NG A, SHAW L. A KAPOSIFORM HEMANGIOENDOTHELIOMA SUCCESSFULLY AND SAFELY TREATED WITH SIROLIMUS: SHOULD SIROLIMUS BE FIRST-LINE TREATMENT FOR THIS INDICATION? PEDIATR-DERMATOL 2016;33 (SUPPL. S1):S57. | 0.00 | Y | 0.00000 | 20160718 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125671691 | 12567169 | 1 | PS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 2 MG/KG/DAY | U | U | 202179 | ||||||||
| 125671691 | 12567169 | 2 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | 0.2 MG WEEKLY | U | 0 | |||||||||
| 125671691 | 12567169 | 3 | SS | SIROLIMUS. | SIROLIMUS | 1 | Unknown | 2 MG/M2/DAY (0.7 MG/DAY) | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125671691 | 12567169 | 1 | Angiosarcoma |
| 125671691 | 12567169 | 2 | Angiosarcoma |
| 125671691 | 12567169 | 3 | Angiosarcoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125671691 | 12567169 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125671691 | 12567169 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |